Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (NASDAQ: BHST) is a biotechnology company that describes itself as a leader in Botanical Synthesis, using its patented plant cell-based platform to grow active plant compounds without cultivating the whole plant. The BioHarvest news stream highlights how this technology underpins both its direct-to-consumer nutraceutical products and its contract development and manufacturing (CDMO) services.
Investors following BHST news can read about developments in the company’s VINIA brand, including capsules, hot beverages, daily chews, and VINIA Blood Flow Hydration, which the company presents as a hydration solution powered by the blood flow benefits of Piceid resveratrol. News items also cover subscriber trends, online channel performance, and the expansion of VINIA into broader health and wellness categories.
Another major theme in BioHarvest’s news is the evolution of its CDMO Services division. Company updates describe new customer contracts in pharmaceuticals, nutrition, fragrance, and nutraceuticals, such as a saffron-derived compound partnership with Saffron Tech and work on a plant-based fragrance compound. Releases also discuss milestones like producing plant-based exosomes at scale in a bioreactor and integrating AI-based tools into a second-generation Botanical Synthesis process.
Capital markets and regulatory announcements form a further part of the BHST news flow, including public offerings under a Form F-3 shelf registration, material change reports, and interim financial results filed on Form 6-K. Readers can use this page to monitor BioHarvest’s operational updates, technology progress, and financing activities in one place.
BioHarvest Sciences (NASDAQ: BHST) reported FY2025 revenue of $34.5M, up 37% year-over-year, and Q4 revenue of $9.1M, up 25% YoY. Gross margin was ~59% for FY2025. Cash and equivalents totaled $23.0M as of Dec 31, 2025. The company completed an oversubscribed institutional financing of $19.9M in November 2025 and raised an additional $10.9M from warrant exercises and debt conversions. 2026 consolidated revenue guidance is $42–48M with adjusted EBITDA loss guidance of ($3–4M). 2026 CDMO revenue guidance is $4–6M (total CDMO incl. intercompany $12–14M) with expected CDMO adjusted EBITDA loss of ($4–5M).
BioHarvest Sciences (NASDAQ: BHST) announced that its CDMO division completed Stage 1 of a multi-stage program, creating the first-ever stable cell culture for a rare, endangered fragrance plant using its Botanical Synthesis platform.
BioHarvest retains 20% ownership of developed compositions; biomass for pre-commercial testing is expected in 6–9 months, with industrial-scale manufacturing anticipated in 12–18 months. Company cites a $23B premium fragrance segment within a $58.9B industry opportunity.
BioHarvest Sciences (NASDAQ: BHST) announced that VINIA is the No.1 Resveratrol Polyphenol nutraceutical brand in the United States as of March 26, 2026.
Key metrics: U.S. revenue > $30 million in 2025, $85 million global cumulative revenue to date, ~85,000 active users, and VINIA.com accounts for ~80% of U.S. VINIA revenue. The company cites Botanical Synthesis technology that preserves plant-cell structure and magnifies piceid resveratrol up to 100x. The #1 ranking is based on NIQ 2025 market projections and Amazon sales estimates.
BioHarvest Sciences (NASDAQ: BHST) will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The company will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and business updates.
Investors can register for the live webcast and replay will be posted in the Investor Relations/Events & Presentations section of the company's website.
BioHarvest (NASDAQ: BHST) announced a board transition on March 5, 2026: Mr. David Tsur will step down after more than four years, and Prof. Hezi Levy is appointed to the Board effective immediately.
Prof. Levy brings decades of Israeli healthcare leadership, including Director General of the Ministry of Health and Head of IDF Medical Corps.
BioHarvest Sciences (NASDAQ: BHST) will participate in the 38th Annual Roth Conference on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. CEO Ilan Sobel is scheduled for one-on-one meetings with institutional investors.
According to the company, BioHarvest completed a successful Q4 2025 financing, is fully funded for near-term CapEx, and has over 85,000 direct customers as it focuses on growth in CDMO and consumer product businesses.
BioHarvest Sciences (NASDAQ: BHST) issued a year-end letter reporting an annualized revenue run rate exceeding US$36 million, gross margins above 60%, and a plan to reach adjusted EBITDA breakeven in the near term. The company reported >85,000 active VINIA users, >90% subscription purchase rate, and 10,000+ verified reviews at a 4.7/5 average rating.
Operational highlights include VINIA Blood Flow Hydration launched in-market, CDMO contract wins in May and October 2025 (including a 25% ownership stake in a saffron-derived compound), AI-enabled discovery services, and a planned 100-ton manufacturing footprint. BioHarvest raised approximately $30.8 million in 2025 to fund growth and manufacturing expansion.
BioHarvest (NASDAQ: BHST) was awarded a $1.6 million grant from the Israeli Innovation Authority under its Bio-Convergence program on December 18, 2025.
The non-dilutive, zero-interest loan will fund development of the company’s second-generation Botanical Synthesis™ platform, including AI tools for process optimization, larger bioreactors for higher-volume production, and expanded autonomous manufacturing to improve scalability and unit economics.
BioHarvest reports it is fully funded for current plans with approximately $25 million in cash; repayment of the IIA loan is contingent on predefined commercial milestones and expected to be paid from future project revenues.
BioHarvest Sciences (NASDAQ: BHST) on December 3, 2025 launched VINIA Blood Flow Hydration, a hydration stick-pack powered by VINIA's Piceid resveratrol and red-grape polyphenols entering the $13 billion U.S. electrolyte drink market. The formula delivers 23 mg red-grape polyphenols including 6 mg rapid-absorption Piceid resveratrol, plus naturally sourced electrolytes: 470 mg sodium, 190 mg potassium, and 80 mg magnesium per serving. The product is shipping nationwide via VINIA.com with free North America delivery, will appear on Amazon by end of December 2025, is Informed Sport tested, and is backed by a 90-day “Feel It or It’s Free” guarantee. Clinical support is cited from Vaisman et al., 2015.
BioHarvest Sciences (NASDAQ: BHST) reported third quarter 2025 results: revenue $9.1M, +39% YoY, gross profit $5.6M (61% margin), and a net loss of $2.5M or $0.14 per share. Management expects Q4 2025 revenue of $9.0–9.5M and adjusted EBITDA of ($0.6)–$0.0M.
Operational highlights include a VINIA user base >75,000, a VIP early adopter launch of VINIA Blood Flow Hydration (market rollout Dec 3), a breakthrough producing plant-based exosomes at scale, and a new CDMO customer (Saffron Tech) with BioHarvest retaining 25% ownership of the compound. The company strengthened its balance sheet via accelerated warrant exercises and debt conversions and a $19.9M institutional equity raise in November.